<DOC>
	<DOCNO>NCT00827814</DOCNO>
	<brief_summary>Increased bladder mass occur consequence bladder outlet obstruction animal patient , relief bladder outlet obstruction revers increase bladder mass . Whether increase bladder mass consequence bladder outlet obstruction also relevant risk factor progression lower urinary tract symptom associate benign prostate hyperplasia decide due lack appropriate data , likely bladder wall thickness routinely measure clinical study and/or routine clinical practice . Despite lack data , many urologist feel increase bladder mass prevent decreased reduce occurrence serious complication . The possibility use bladder wall thickness data criterion benign prostate hyperplasia intervention outcome criterion benign prostate hyperplasia treatment propose . Detrusor hypertrophy associate bladder outlet obstruction image suprapubic ultrasound , bladder mass quantify evaluation bladder wall thickness bladder volume . Bladder wall hypertrophy find correlate detrusor function . Independent study show surgical treatment benign prostatic obstruction result significant decrease bladder mass . Preliminary data suggest possibility medical treatment alpha-adrenergic antagonist might also produce reduction bladder wall hypertrophy . The investigator assume prevention benign prostate hyperplasia progression alpha-adrenergic antagonist 5 alpha reductase inhibitor may result bladder function protection . To knowledge study evaluate effect 5 alpha reductase inhibitor bladder function . Therefore , investigator plan conduct prospective trial evaluate effect 5 alpha reductase inhibitor bladder function evaluation bladder wall thickness low urinary tract symptom .</brief_summary>
	<brief_title>Effect Dutasteride Bladder Wall Hypertrophy Patients With Benign Prostatic Obstruction</brief_title>
	<detailed_description>1 Objective 1.1 Primary Objective : To explore efficacy Dutasteride reduce bladder wall hypertrophy baseline 6 month treatment male patient benign prostatic obstruction . 1.2 Secondary Objective : 1 . To explore efficacy Dutasteride reduce LUTS symptom , number micturition , number urgency episodes baseline 6 month treatment 2 . To explore efficacy Dutasteride urodynamic parameter baseline 6 month treatment . 3 . To explore efficacy Dutasteride tolerability , safety , patient perception quality life baseline 6 month treatment . 2 Endpoints 2.1 Primary Endpoint : Percent ( numeric ) change ultrasound-estimated bladder weight ( UEBW ) baseline 6 month treatment 2.2 Secondary Endpoint : Urodynamic parameter : From baseline 6 month treatment • Percentage numeric change - Maximum flow rate ( mL/s ) - Average flow rate ( mL/s ) - Post-void residual urine volume ( mL ) Micturition diary efficacy parameter : From baseline 6 month treatment - Percentage numeric change micturition frequency/24 hour - Percentage numeric change mean volume void per micturition - Percentage numeric change mean number severity urgency per micturition Prostate volume parameter : • Change prostate volume TRUS baseline 6 month treatment . • Change serum PSA baseline 6 month treatment . Quality life parameter : • Change Bother Score IPSS score baseline 6 month treatment LUTS Symptom parameter : • Change IPSS score baseline 6 month treatment - total score : sum 7 question - storage score : sum question 2 , 4 7 - void score : sum question 1 , 3 , 5 6 LUTS outcome score ( LOS ) • Change LOS baseline 6 month treatment Patient perception : - Patient perception treatment benefit 3 6 month treatment - Change patient perception urgency baseline 3 6 month treatment Safety parameter : • Incidence severity adverse event • Incidence reason withdrawal 3 . STUDY DESIGN AND METHODS Study Design : This 6-month prospective Phase IV study explore effect bladder function Dutasteride male patient benign prostatic obstruction .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>1 . Age≥50 &lt; 80 year old 2 . Presence LUTS least 3 month 3 . IPSS≥15 4 . Bladder outlet obstruction confirm pressureflow study ( BOOI &gt; 20 ) 5 . Prostate volume measure TRUS ≥ 30ml &lt; 100ml 6 . Able comply prescribe treatment protocol evaluation . 1 . Patients neurogenic void disorder 2 . Patients prostate bladder cancer 3 . Patients underwent urethral , prostate bladder neck surgery 4 . Patients urethral stricture bladder neck contracture 5 . Serum PSA≥4ng/ml ( patient confirm malignancy prostate biopsy include ) . 6 . Patients medicate 5ARI within 6 month 7 . Patients agree inform consent</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>